Public procurement notice: Voluntary Ex Ante Transparency Notice
Published: 2021-11-10
Buyer: SYKEHUSINNKJØP HF
Country: NO
Contract type: Supplies
Procedure: Contract award without prior publication
CPV classification: 33600000: Pharmaceutical products
Estimated value: 24000000 NOK
Award criteria: Lowest price

Technical requirements: Voluntary ex ante transparency notice - LIS 2201h-1 Chlorhexidine and alcoholic chlorhexidine (pharmaceuticals)
Sykehusinnkjøp HF, Divisjon legemidler [the Norwegian Hospital Procurement Trust, the Pharmaceutical Division] is collecting offers for pharmaceuticals used by the health trusts. The Pharmaceutical Division has issued a prior information notice about a contest for Chlorhexidine that can be classified as pharmaceuticals and biocides. In the pharmaceuticals group there is only one supplier in the Norwegian market who markets Chlorhexidine embrocation and alcoholic chlorhexidine.
On this basis, the Norwegian Hospital Procurement Trust, Pharmaceutical Division, intends to enter into contracts between the regional health trusts (the contracting authorities) and Fresenius Kabi Norge AS (the supplier) without announcing a separate contest for Chlorhexidine classified as a pharmaceutical.
Sykehusinnkjøp HF, Divisjon legemidler [the Norwegian Hospital Procurement Trust, the Pharmaceutical Division] is collecting offers for pharmaceuticals used by the health trusts. The Pharmaceutical Division has issued a prior information notice about a contest for Chlorhexidine that can be classified as pharmaceuticals and biocides. In the pharmaceuticals group there is only one supplier in the Norwegian market who markets Chlorhexidine embrocation and alcoholic chlorhexidine.
On this basis, the Norwegian Hospital Procurement Trust, Pharmaceutical Division, intends to be in charge of contracts between the regional health trusts (the contracting authorities) and Fresenius Kabi Norge AS (the supplier) without announcing a separate contest for Chlorhexidine classified as a pharmaceutical.
The health companies that are under the regional health trusts have an option to enter into the contracts. The same applies for non-profit institutions/hospitals with an operational contract with each health region. The Pharmaceutical Division has examined the market situation and is of the opinion that it is not possible to hold a new contest or that a supplier other than Fresenius Kabi Norge AS can deliver the product in the same contract period (01.02.2022 - 31.01.2024), and that the situation that has occurred is not the contracting authority’s fault, nor something that the contracting authority could predict. The Pharmaceutical Division therefore means there is LIS therefore believes that there is a legal basis to carry out the procurement without a contest. Refer to the Public Procurement Regulation §13-4, letter b, no. 3. The Pharmaceutical Division requests that those with objections to the intended contract award submit feedback before the waiting period expires on 14.11.2021. If no objections are received, a contract will be signed after the waiting period has expired.
Sykehusinnkjøp HF, Divisjon legemidler [the Norwegian Hospital Procurement Trust, the Pharmaceutical Division] is collecting offers for pharmaceuticals used by the health trusts. The Pharmaceutical Division has issued a prior information notice about a contest for Chlorhexidine that can be classified as pharmaceuticals and biocides. In the pharmaceuticals group there is only one supplier in the Norwegian market who markets Chlorhexidine embrocation and alcoholic chlorhexidine.
On this basis, the Norwegian Hospital Procurement Trust, Pharmaceutical Division, intends to be in charge of contracts between the regional health trusts (the contracting authorities) and Fresenius Kabi Norge AS (the supplier) without announcing a separate contest for Chlorhexidine classified as a pharmaceutical..
The health companies that are under the regional health trusts have an option to enter into the contracts. The same applies for non-profit institutions/hospitals with an operational contract with each health region. The Pharmaceutical Division has examined the market situation and is of the opinion that it is not possible to hold a new contest or that a supplier other than Fresenius Kabi Norge AS can deliver the product in the same contract period (01.02.2022 - 31.01.2024), and that the situation that has occurred is not the contracting authority’s fault, nor something that the contracting authority could predict. The Pharmaceutical Division therefore means there is LIS therefore believes that there is a legal basis to carry out the procurement without a contest. Refer to the Public Procurement Regulation §13-4, letter b, no. 3. The Pharmaceutical Division requests that those with objections to the intended contract award submit feedback before the waiting period expires on 14.11.2021. If no objections are received, a contract will be signed after the waiting period has expired.


Winner: Fresenius Kabi Norge AS
Award value: 24000000